Achievement of corticosteroid-free clinical endpoints in subjects with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 trial

被引：0

作者：

Sands, B. E. ^{[1
]}

Rubin, D. T. ^{[2
]}

Panes, J. ^{[3
]}

Gecse, K. B. ^{[4
]}

Leung, Y. ^{[5
]}

Goetsch, M. ^{[6
]}

Wang, W. ^{[7
]}

Shan, K. ^{[8
]}

Woolcott, J. ^{[9
]}

Smith, C. C. ^{[9
]}

Wosik, K. ^{[10
]}

Schreiber, S. W. ^{[11
]}

机构：

[1] Icahn Sch Med Mt Sinai, Dr Henry Janowitz Div Gastroenterol, Gastroenterol, New York, NY USA

[2] Univ Chicago Med, Sect Gastroenterol Hepatol & Nutr, Chicago, IL USA

[3] Hosp Clin Barcelona IDIBAPS, Gastroenterol, CIBERehd, Barcelona, Spain

[4] Amsterdam UMC, Gastroenterol, Amsterdam, Netherlands

[5] Univ British Columbia, Gastroenterol, Vancouver, BC, Canada

[6] Pfizer AG, Global Clin Dev, Zurich, Switzerland

[7] Pfizer Inc, Biostat, Collegeville, PA USA

[8] Pfizer Inc, Global Project Dev Inflammat Immunol, New York, NY USA

[9] Pfizer Inc, Global Med Affairs Gastroenterol, Collegeville, PA USA

[10] Pfizer Inc, Global Med Affairs Gastroenterol, Kirkland, PQ, Canada

[11] Univ Kiel, Univ Hosp Schleswig Holstein, Internal Med, Dept Internal Med 1, Kiel, Germany

来源：

JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

DOP41

引用

页码：I106 / I107

页数：3

共 50 条

[1] ACHIEVEMENT OF CORTICOSTEROID-FREE CLINICAL ENDPOINTS IN SUBJECTS WITH ULCERATIVE COLITIS: AN ANALYSIS OF THE PHASE 3 ELEVATE UC 52 TRIAL
Sands, Bruce E.
Rubin, David T.
Panes, Julian
Gecse, Krisztina
Leung, Yvette
Goetsch, Martina
Wang, Wenjin
Shan, Kevin
Woolcott, John
Smith, Christina C.
Wosik, Karolina
Schreiber, Stefan
GASTROENTEROLOGY, 2023, 164 (06) : S1084 - S1084
[2] Achievement of stringent histologic and composite endpoints in subjects with moderately to severely active ulcerative colitis treated with etrasimod: a post hoc analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
Magro, F.
Peyrin-Biroulet, L.
Sands, B. E.
Danese, S.
Jairath, V.
Goetsch, M.
Bhattacharjee, A.
Wu, J.
Branquinho, D. Ferreira
Modesto, I.
Feagan, B. G.
JOURNAL OF CROHNS & COLITIS, 2023, 17 : 728 - 729
[3] ACHIEVEMENT OF STRINGENT HISTOLOGIC AND COMPOSITE ENDPOINTS IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH ETRASIMOD: A POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
Magro, Fernando
Peyrin-Biroulet, Laurent
Sands, Bruce E.
Danese, Silvio
Jairath, Vipul
Goetsch, Martina
Bhattacharjee, Abhishek
Wu, Joseph
Branquinho, Diogo
Modesto, Irene
Feagan, Brian G.
GASTROENTEROLOGY, 2023, 164 (06) : S1092 - S1093
[4] ETRASIMOD FOR THE TREATMENT OF ULCERATIVE COLITIS: ANALYSIS OF INFECTION RATES FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 CLINICAL TRIALS
Regueiro, Miguel D.
Siegmund, Britta
Yarur, Andres J.
Steinwurz, Flavio
Gecse, Krisztina
Goetsch, Martina
Bhattacharjee, Abhishek
Wu, Joseph
Green, Jesse
McDonnell, Aoibhinn
Crosby, Catherine
Lazin, Krisztina
Branquinho, Diogo
Modesto, Irene
Abreu, Maria T.
GASTROENTEROLOGY, 2023, 164 (06) : S1105 - S1106
[5] Etrasimod for the treatment of ulcerative colitis: analysis of infection rates from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 clinical trials
Regueiro, M.
Siegmund, B.
Yarur, A.
Steinwurz, F.
Gecse, K. B.
Goetsch, M.
Bhattacharjee, A.
Wu, J.
Green, J.
McDonnell, A.
Crosby, C.
Lazin, K.
Branquinho, D. Ferreira
Modesto, I.
Abreu, M. T.
JOURNAL OF CROHNS & COLITIS, 2023, 17 : 689 - 690
[6] Corticosteroid-Free Efficacy Outcomes in Patients Receiving Concomitant Corticosteroids at Baseline in the Etrasimod ELEVATE UC 52 Trial
Sands, Bruce E.
Leung, Yvette
Rubin, David T.
Gecse, Krisztina B.
Panes, Julian
Goetsch, Martina
Wang, Wenjin
Shan, Kevin
Woolcott, John C.
Smith, Christina C.
Wosik, Karolina
Schreiber, Stefan
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S876 - S877
[7] Efficacy of etrasimod on symptomatic relief in patients with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
Chaparro, M.
Armuzzi, A.
Irving, P. M.
Allez, M.
Dubinsky, M. C.
Sands, B. E.
Goetsch, M.
Wang, W.
Shan, K.
Woolcott, J.
Bartolome, L.
Wosik, K.
Panaccione, R.
JOURNAL OF CROHNS & COLITIS, 2023, 17 : I107 - I110
[8] EFFICACY OF ETRASIMOD ON SYMPTOMATIC RELIEF IN PATIENTS WITH ULCERATIVE COLITIS: AN ANALYSIS OF THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
Chaparro, Maria
Armuzzi, Alessandro
Irving, Peter M.
Allez, Matthieu
Dubinsky, Marla C.
Sands, Bruce E.
Goetsch, Martina
Wang, Wenjin
Shan, Kevin
Woolcott, John
Bartolome, Lauren
Wosik, Karolina
Panaccione, Remo
GASTROENTEROLOGY, 2023, 164 (06) : S1099 - S1100
[9] Etrasimod Corticosteroid-Free Efficacy, Impact of Concomitant Corticosteroids on Efficacy and Safety, and Corticosteroid-Sparing Effect in Ulcerative Colitis: Analyses of the ELEVATE UC Clinical Program
Sands, Bruce E.
Leung, Yvette
Rubin, David T.
Gecse, Krisztina B.
Panes, Julian
Goetsch, Martina
Wang, Wenjin
Woolcott, John C.
Smith, Christina C.
Wosik, Karolina
Schreiber, Stefan
JOURNAL OF CROHNS & COLITIS, 2024,
[10] MAINTENANCE OF WEEK 12 RESPONSES THROUGH WEEK 52 WITH ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC 52 TRIAL
Sands, Bruce E.
Vermeire, Severine
Dubinsky, Marla C.
Feagan, Brian G.
Panaccione, Remo
Jairath, Vipul
Yarur, Andres J.
Chiorean, Michael V.
Panes, Julian
Goetsch, Martina
Rabbat, Christopher J.
Shah, Pooja
Wu, Joseph
Ghosh, Subrata
GASTROENTEROLOGY, 2023, 164 (06) : S1084 - S1085

← 1 2 3 4 5 →